What type of study is this?

This is a In Vitro Study study.

What question did this study set out to answer?

The study explores the potential of DIO2 inhibitors as tools for modulating local T3 production and regulatory testing.

March 15, 2026

Novel Deiodinase 2-Selective Inhibitors—Possible Reference Substances for Regulatory In Vitro Tests for Endocrine Disruptors and Drugs Targeting T3-Dependent Processes

Puntos clave

The study explores the potential of DIO2 inhibitors as tools for modulating local T3 production and regulatory testing.
Identified specific DIO2 inhibitors including FDA-approved drugs and assessed their pharmacological potential.
Evaluated the use of reference compounds for regulatory in vitro tests on endocrine disruptors.
Confirmed that drugs like ibrutinib can affect the availability of T3, influencing metabolic processes.
Proposed that these inhibitors can serve as references in validation processes for testing endocrine disruptors.

Resumen

Specific DIO2 inhibitors, such as the FDA-approved drugs racecadotril and ibrutinib and the tyrosine kinase inhibitor rociletinib, might serve as a future toolbox for reversible pharmacological interference with the local provision of DIO2-generated T3 from T4 during development, tissue regeneration, and various DIO2-dependent metabolic processes. Furthermore, they can serve as reference compounds for the development and validation of regulatory in vitro tests. Identified FDA-approved drugs warrant a closer look at potential disturbances of local TH availability.

Preguntar a la IA

Me gusta

Guardar